A new study reports that adding mindfulness-based cognitive therapy to standard antidepressant treatment reduces depressive symptoms more effectively than medication alone and is linked to distinctive changes in brain activity. Lead author Seyed Ruhollah Hosseini of Ferdowsi University of Mashhad, Iran, and colleagues conducted the research, published in Mindfulness, to explore how mindfulness practices alter the brain’s electrical networks when layered on top of routine pharmacological care.
Major depressive disorder involves persistent low mood, a loss of interest in daily life, and a range of physical or cognitive changes that can disrupt functioning. Treatments typically include antidepressant medication, but many patients do not achieve full relief with drugs alone. Clinicians sometimes combine pharmacotherapy with psychological therapies to improve outcomes.
The intervention studied combined standard antidepressant treatment with an eight-week mindfulness-based cognitive therapy programme. MBCT comprises meditation practices, such as deep breathing and guided body scans, alongside cognitive strategies designed to curb negative thinking. The aim is to help patients observe thoughts without judgment and reduce rumination that can relapse depressive symptoms.
In this trial, 66 women with major depressive disorder seeking treatment at psychiatric clinics were prescribed a daily dose of citalopram. They were randomised to either continue medication with usual psychiatric monitoring or to receive the same medication plus the MBCT programme, delivered as weekly two-hour group sessions and daily home meditation using audio recordings.
Clinical progress was assessed with the Beck Depression Inventory-II before and after the eight-week period. Brain activity was measured using an electroencephalogram, recorded while participants rested with their eyes closed. The researchers then used specialised software to estimate where brain signals originate within the brain’s structure.
Both groups showed improvements in depressive symptoms over the eight weeks. At baseline, participants in both groups averaged around 28 on the depression scale. After treatment, the medication-only group averaged about 13, while those who participated in MBCT saw their average fall to 11.6, a difference the researchers describe as robust beyond the medication’s effects alone.
Neurophysiological data revealed distinct patterns in the mindfulness group. Theta wave activity decreased in regions likely corresponding to the left insula, a brain area implicated in processing emotions and bodily sensations. In addition, the mindfulness group exhibited increased upper alpha wave activity across parts of the right hemisphere, including frontal and parietal regions, and heightened low beta activity in the left insula area. These changes point to a reorganisation of neural networks involved in emotional regulation and bodily awareness following mindfulness training.
The researchers caution that the EEG setup used a 19-electrode system, which offers limited spatial resolution. As a result, the precise anatomical localisation reported by the software remains probabilistic rather than definitive. They note that confirming these regions will require higher-density electrode arrays or functional imaging techniques.
Limitations include that the study involved only women, so findings may not generalise to men or non-binary individuals. The trial was not blinded, which can influence self-reported outcomes, and the authors call for longer follow-up to determine whether brain and mood benefits persist. They also suggest incorporating objective clinician assessments alongside self-reports in future work.
The study, titled Can Mindfulness-Based Cognitive Therapy Change the Cortical Electrical Activity of the Brain in Major Depressive Disorder?, is by Seyed Ruhollah Hosseini, Nikzad Ghanbari, Maryam Shamsaei and Elaheh Kardan Ghabel.
